US20070066812A1 - Fibroblast growth factor homologous factor-2 and methods of use - Google Patents
Fibroblast growth factor homologous factor-2 and methods of use Download PDFInfo
- Publication number
- US20070066812A1 US20070066812A1 US11/514,821 US51482106A US2007066812A1 US 20070066812 A1 US20070066812 A1 US 20070066812A1 US 51482106 A US51482106 A US 51482106A US 2007066812 A1 US2007066812 A1 US 2007066812A1
- Authority
- US
- United States
- Prior art keywords
- fhf
- dna
- cell
- sequence
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 title claims description 5
- 108090000047 fibroblast growth factor 13 Proteins 0.000 title claims description 5
- 238000000034 method Methods 0.000 title description 34
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000012634 fragment Substances 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 44
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 40
- 229920001184 polypeptide Polymers 0.000 abstract description 37
- 102000040430 polynucleotide Human genes 0.000 abstract description 28
- 108091033319 polynucleotide Proteins 0.000 abstract description 28
- 239000002157 polynucleotide Substances 0.000 abstract description 28
- 102000018233 Fibroblast Growth Factor Human genes 0.000 abstract description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 229940126864 fibroblast growth factor Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 75
- 108090000623 proteins and genes Proteins 0.000 description 47
- 108020004414 DNA Proteins 0.000 description 34
- 230000014509 gene expression Effects 0.000 description 34
- 239000002299 complementary DNA Substances 0.000 description 32
- 150000001413 amino acids Chemical group 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 239000013598 vector Substances 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 23
- 101150021185 FGF gene Proteins 0.000 description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 19
- 230000027455 binding Effects 0.000 description 18
- 230000000692 anti-sense effect Effects 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 16
- 239000002502 liposome Substances 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 12
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 229930182817 methionine Natural products 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 10
- 101000878176 Homo sapiens Fibroblast growth factor 13 Proteins 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 230000002062 proliferating effect Effects 0.000 description 10
- 230000001177 retroviral effect Effects 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 102000053642 Catalytic RNA Human genes 0.000 description 8
- 108090000994 Catalytic RNA Proteins 0.000 description 8
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 108091092562 ribozyme Proteins 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000003102 growth factor Substances 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 239000003999 initiator Substances 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 210000000653 nervous system Anatomy 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 210000005003 heart tissue Anatomy 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 208000015122 neurodegenerative disease Diseases 0.000 description 5
- 239000002853 nucleic acid probe Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- -1 FHF-2 Substances 0.000 description 4
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 4
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 description 4
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 4
- 102000002265 Human Growth Hormone Human genes 0.000 description 4
- 108010000521 Human Growth Hormone Proteins 0.000 description 4
- 239000000854 Human Growth Hormone Substances 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000020446 Cardiac disease Diseases 0.000 description 3
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 3
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001246 colloidal dispersion Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 108010059616 Activins Proteins 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 description 2
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 2
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 2
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 2
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241000713858 Harvey murine sarcoma virus Species 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000713869 Moloney murine leukemia virus Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101100446506 Mus musculus Fgf3 gene Proteins 0.000 description 2
- 101000878177 Mus musculus Fibroblast growth factor 13 Proteins 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000251131 Sphyrna Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001130 astrocyte Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 210000004090 human X chromosome Anatomy 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000001455 metallic ions Chemical class 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000714235 Avian retrovirus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101710134292 Dorsalin-1 Proteins 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 108050003239 Fibroblast growth factor 12 Proteins 0.000 description 1
- 102100028417 Fibroblast growth factor 12 Human genes 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010090296 Growth Differentiation Factor 1 Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710094503 Metallothionein-1 Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000004422 Phospholipase C gamma Human genes 0.000 description 1
- 108010056751 Phospholipase C gamma Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 101710182846 Polyhedrin Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 108010057863 heparin receptor Proteins 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates generally to growth factors and specifically to a novel member of the fibroblast growth factor family, denoted fibroblast growth factor homologous factor-2 (FHF-2) and the polynucleotide encoding FHF-2.
- FHF-2 fibroblast growth factor homologous factor-2
- the fibroblast growth factor family encompasses a group of structurally related proteins with a wide range of growth promoting, survival, and/or differentiation activities in vivo and in vitro (reviewed in Baird, A., and Gospodarowicz, D. Ann N.Y. Acad. Sci. 638: 1, 1991; Eckenstein, F. P., J. Neurobiology 25: 1467, 1994; Mason, I. J. Cell 78: 547, 1994). As of December 1994, nine members of this family had been characterized by molecular cloning.
- aFGF/FGF-1 acidic fibroblast growth factor
- bFGF/FGF-2 basic fibroblast growth factor
- aFGF/FGF-1 acidic fibroblast growth factor
- bFGF/FGF-2 basic fibroblast growth factor
- FGF family Additional members include: int-2/FGF-3, identified as one of the frequent sites of integration of the mouse mammary tumor virus, and therefore a presumptive oncogenic factor (Smith et al., EMBO J. 7: 1013, 1988); FGF-4 (Delli-Bovi et al., Cell 50: 729, 1987) and FGF-5 (Zhan et al., Mol. Cell Biol.
- FGF-6 isolated by molecular cloning based on its homology to FGF-4 (Marics et al., Oncogene 4: 335 (1989); keratinocyte growth factor/ FGF-7, identified as a mitogen for keratinocytes (Finch et al., Science 245: 752.1989); FGF-8 as an androgen-induced mitogen for mammary carcinoma cells (Tanaka et al., Proc. Natl. Acad. Sci. USA 89: 8928, 1992); and FGF-9 as a mitogen for primary astrocytes (Miyamoto et al., Mol. Cell Biol. 13: 4251, 1993).
- FGFs including aFGF and bFGF, lack a classical signal sequence; the mechanism by which they are secreted is not known.
- aFGF, bFGF, and FGF-7/KGF have been shown to exert some or all of their biological activity through high affinity binding to cell surface tyrosine kinase receptors (e.g., Lee, P. L. et al., Science 245: 57, 1989; reviewed in Johnson, D. E. and Williams, L. T., Adv. Cancer Res. 60: 1, 1993).
- Many members of the FGF family also bind tightly to heparin, and a terniary complex of heparin, FGF, and transmembrane receptor may be the biologically relevant signalling species.
- heparin bind tightly to heparin
- a terniary complex of heparin, FGF, and transmembrane receptor may be the biologically relevant signalling species.
- Identification and characterization of new members of the FGF family will provide insights into the mechanisms by which cells and organs control their growth, survival, senescence, differentiation, and recovery from injury.
- the present invention provides a cell growth, survival and differentiation factor, FHF-2, and a polynucleotide sequence which encodes the factor. This factor is involved in the growth, survival, and or differentiation of cells within the central nervous system (CNS) and in the heart.
- CNS central nervous system
- the invention provides a method for detecting alterations in FHF-2 gene expression which are diagnostic of neurodegenerative, neoplastic, or cardiac disorders.
- the invention provides a method for treating a neurodegenerative, neoplastic or cardiac disorder by enhancing or suppressing the expression or activity of FHF-2.
- FIG. 1 shows the nucleotide and predicted amino acid sequence of human FHF-2 (SEQ ID NO:1 and SEQ ID NO:2).
- FIGS. 2A and B show an alignment of the amino acid sequence of human FHF-2 and each of the published nine members of the FGF family. conserveed residues are highlighted.
- the FGF family members are: aFGF/FGF-1 (SEQ ID NO:22) (Jaye et al., Science 233: 541, 1986), bFGF/FGF-2 (SEQ ID NO:24) (Abraham et al., Science 233: 545, 1986), int-2/FGF-3 (SEQ ID NO: 17) (Smith et al., EMBO J.
- FGF-4 SEQ ID NO:19
- FGF-5 SEQ ID NO: 18
- FGF-6 SEQ ID NO:20
- keratinocyte growth factor/FGF-7 SEQ ID NO:23
- FGF-8 SEQ ID NO: 16
- FGF-9 FGF-9
- FIG. 3 shows a dendrogram in which the length of each path connecting any pair of FGF family members is proportional to the degree of amino acid sequence divergence of that pair.
- FIG. 4 shows the location of the gene encoding FHF-2 on the human X-chromosome.
- a Southern blot was prepared from DNA derived from mouse-human or hamster-human hybrid cell lines, each of which contains a single human chromosome, indicated above each lane. The human specific hybridization is found on the X-chromosome.
- FIG. 5 shows the production of FHF-2 in transfected human embryonic kidney cells. Proteins were labeled biosynthetically with 35 S-methionine and resolved by SDS-polyacrylamide gel electrophoresis. Lanes 1, 3, 5, and 7: total cell protein; lanes 2, 4, 6, and 8: protein present in the medium (secreted protein). Lanes 1 and 2, mock transfected cells; lanes 3 and 4, transfection with cDNA encoding FHF-1, a closely related member of the FGF family; lanes 5 and 6, transfection with cDNA encoding FHF-2; lanes 7 and 8, transfection with cDNA encoding human growth hormone. Arrows indicate the FHF-1 and FHF-2 protein bands. Protein standards are shown to the left; from top to bottom their molecular masses are 220, 97, 66, 46, 30, 21.5, and 14.3 kD.
- FIG. 6 shows the tissue specificity of FHF-2 expression.
- Ten micrograms of total RNA from the indicated mouse tissues was prepared (Chomczinski & Sacchi. Anal. Biochem. 162: 156, 1987) and used for RNAse protection (Ausabel et al., Current Protocols in Molecular Biology; New York: Wiley Interscience, 1987) with a mouse FHF-2 antisense probe that spanned 197 bases of the most 3′ coding region exon and the adjacent upstream 335 bases of intron sequence.
- RNAse protection at the size expected for the 197 base exon region of the probe was observed with RNA from brain, eye, and heart. A longer exposure reveals barely visible bands in all of the other tissues but not in the tRNA control sample.
- the present invention provides a growth factor, FHF-2, and a polynucleotide sequence encoding FHF-2.
- FHF-2 is expressed at high levels in brain and heart tissues.
- the invention provides a method for detection of a cell proliferative or immunologic disorder of central nervous system or cardiac tissue origin which is associated with FHF-2 expression or function.
- the invention provides a method for treating a cell proliferative or immunologic disorder by using an agent which suppresses or enhances FHF-2 expression or activity.
- FHF-2 protein of this invention The structural homology between the FHF-2 protein of this invention and the members of the FGF family, indicates that FHF-2 is a new member of the family of growth factors. Based on the known activities of many of the other members, it can be expected that FHF-2 will also possess biological activities that will make it useful as a diagnostic and therapeutic reagent.
- TGF TGF-1
- dorsalin-1 Another family member, namely dorsalin-1, is capable of promoting the differentiation of neural crest cells (Basler, et al., Cell, 73:687, 1993).
- the inhibins and activins have been shown to be expressed in the brain (Meunier, et al., Proc. Nat'l. Acad.
- TGF family member namely GDF-1
- GDF-1 is nervous system-specific in its expression pattern (Lee, Proc. Nat'l. Acad. Sci., USA, 88:4250, 1991), and certain other family members, such as Vgr-1 (Lyons, et al., Proc. Nat'l. Acad.
- FHF-2 may also possess activities that relate to the function of the nervous system.
- the known neurotrophic activities of other members of this family and the expression of FHF-2 in muscle suggest that one activity of FHF-2 may be as a trophic factor for motor neurons.
- FHF-2 may have neurotrophic activities for other neuronal populations.
- FHF-2 may have in vitro and in vivo applications in the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis, or in maintaining cells or tissues in culture prior to transplantation.
- myoblasts may be used as a vehicle for delivering genes to muscle for gene therapy, the properties of FHF-2, namely the elevated expression in heart tissue (i.e., muscle), could be exploited for maintaining cells prior to transplantation or for enhancing the efficiency of the fusion process.
- the invention provides substantially pure fibroblast growth factor homologous factor-2 (FHF-2) characterized by having a molecular weight of about 30 kD as determined by reducing SDS-PAGE and having essentially the amino acid sequence of SEQ ID NO:2.
- FHF-2 fibroblast growth factor homologous factor-2
- substantially pure refers to FHF-2 which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated.
- the substantially pure polypeptide will yield a single major band on a non-reducing polyacrylamide gel.
- the purity of the FHF-2 polypeptide can also be determined by amino-terminal amino acid sequence analysis.
- FHF-2 polypeptide includes functional fragments of the polypeptide, as long as the activity of FHF-2 remains. Smaller peptides containing the biological activity of FHF-2 are included in the invention.
- the invention provides polynucleotides encoding the FHF-2 protein. These polynucleotides include DNA, cDNA and RNA sequences which encode FHF-2. It is understood that all polynucleotides encoding all or a portion of FHF-2 are also included herein, as long as they encode a polypeptide with FHF-2 activity. Such polynucleotides include naturally occurring, synthetic, and intentionally manipulated polynucleotides. For example, FHF-2 polynucleotide may be subjected to site-directed mutagenesis. The polynucleotide sequence for FHF-2 also includes antisense sequences.
- the polynucleotides of the invention include sequences that are degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the invention as long as the amino acid sequence of FHF-2 polypeptide encoded by the nucleotide sequence is functionally unchanged.
- the sequence contains an open reading frame encoding a polypeptide 245 amino acids in length.
- the human FHF-2 inititiator methionine codon shown in FIG. 1 at position 352-354 corresponds to the location of the initiator methionine codon of another FGF family member, FHF-1, when the two sequences are aligned; a good consensus ribosome binding site (-TGGCCATGG; Kozak, Nucleic Acids Res., 15: 8125, 1987) is found at this position.
- the next methionine codon within the open reading frame is encountered 124 codons 3′ of the putative initiator methionine codon.
- the amino-terminus of the primary translation product of FHF-2 does not conform to the consensus sequence for a signal peptide to direct cotranslational insertion across the endoplasmic reticulum membrane.
- the FHF-2 sequence has one potential asn-X-ser/thr site for asparagine-linked glycosylation four amino acids from the carboxy-terminus.
- the human FHF-2 nucleotide sequence is SEQ ID NO:1 and the deduced amino acid sequence is probably SEQ ID NO:2.
- the polynucleotide encoding FHF-2 includes SEQ ID NO:1 as well as nucleic acid sequences complementary to SEQ ID NO:1.
- a complementary sequence may include an antisense nucleotide.
- the sequence is RNA
- the deoxynucleotides A, G, C, and T of SEQ ID NO:1 is replaced by ribonucleotides A, G, C, and U, respectively.
- fragments of the above-described nucleic acid sequences that are at least 15 bases in length, which is sufficient to permit the fragment to selectively hybridize to DNA that encodes the protein of SEQ ID NO:2 under physiological conditions. Specifically, the fragments should hybridize to DNA encoding FHF-2 protein under stringent conditions.
- the most homologous FGF family member is FGF-9, which shares 28% amino acid identity with FHF-2, when aligned with 6 gaps.
- Minor modifications of the FHF-2 primary amino acid sequence may result in proteins which have substantially equivalent activity as compared to the FHF-2 polypeptide described herein.
- Such proteins include those as defined by the term “having essentially the amino acid sequence of SEQ ID NO.2”. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by these modifications are included herein as long as the biological activity of FHF-2 still exists. Further, deletion of one or more amino acids can also result in a modification of the structure of the resultant molecule without significantly altering its biological activity. This can lead to the development of a smaller active molecule which would have broader utility. For example, one can remove amino or carboxy terminal amino acids which are not required for FHF-2 biological activity.
- the nucleotide sequence encoding the FHF-2 polypeptide of the invention includes the disclosed sequence (SEQ ID NO:2), and conservative variations thereof.
- the term “conservative variation” as used herein denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like.
- the term “conservative variation” also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.
- DNA sequences of the invention can be obtained by several methods.
- the DNA can be isolated using hybridization techniques which are well known in the art. These include, but are not limited to: 1) hybridization of genomic or cDNA libraries with probes to detect homologous nucleotide sequences, 2) polymerase chain reaction (PCR) on genomic DNA or cDNA using primers capable of annealing to the DNA sequence of interest, and 3) antibody screening of expression libraries to detect cloned DNA fragments with shared structural features.
- hybridization techniques which are well known in the art. These include, but are not limited to: 1) hybridization of genomic or cDNA libraries with probes to detect homologous nucleotide sequences, 2) polymerase chain reaction (PCR) on genomic DNA or cDNA using primers capable of annealing to the DNA sequence of interest, and 3) antibody screening of expression libraries to detect cloned DNA fragments with shared structural features.
- the FHF-2 polynucleotide of the invention is derived from a mammalian organism, and most preferably from human. Screening procedures which rely on nucleic acid hybridization make it possible to isolate any gene sequence from any organism, provided the appropriate probe is available. Oligonucleotide probes, which correspond to a part of the sequence encoding the protein in question, can be synthesized chemically. This requires that short, oligopeptide stretches of amino acid sequence must be known. The DNA sequence encoding the protein can be deduced from the genetic code, however, the degeneracy of the code must be taken into account. It is possible to perform a mixed addition reaction when the sequence is degenerate.
- hybridization is preferably performed on either single-stranded DNA or denatured double-stranded DNA.
- Hybridization is particularly useful in the detection of cDNA clones derived from sources where an extremely low amount of mRNA sequences relating to the polypeptide of interest are present.
- stringent hybridization conditions directed to avoid non-specific binding, it is possible, for example, to allow the autoradiographic visualization of a specific cDNA clone by the hybridization of the target DNA to that single probe in the mixture which is its complete complement (Wallace, et al., Nucl. Acid Res., 9:879, 1981; Maniatis, et al., Molecular Cloning: A Laboratory Manual , Cold Spring Harbor, N.Y. 1989).
- DNA sequences encoding FHF-2 can also be obtained by: 1) isolation of double-stranded DNA sequences from the genomic DNA; 2) chemical manufacture of a DNA sequence to provide the necessary codons for the polypeptide of interest; and 3) in vitro synthesis of a double-stranded DNA sequence by reverse transcription of mRNA isolated from a eukaryotic donor cell. In the latter case, a double-stranded DNA complement of mRNA is eventually formed which is generally referred to as cDNA.
- genomic DNA isolates are the least common. This is especially true when it is desirable to obtain the microbial expression of mammalian polypeptides due to the presence of introns.
- DNA sequences are frequently the method of choice when the entire sequence of amino acid residues of the desired polypeptide product is known.
- the direct synthesis of DNA sequences is not possible and the method of choice is the synthesis of cDNA sequences.
- the standard procedures for isolating cDNA sequences of interest is the formation of plasmid- or phage-carrying cDNA libraries which are derived from reverse transcription of mRNA which is abundant in donor cells that have a high level of genetic expression. When used in combination with polymerase chain reaction technology, even rare expression products can be cloned.
- the production of labeled single or double-stranded DNA or RNA probe sequences duplicating a sequence putatively present in the target cDNA may be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single-stranded form (Jay, et al., Nucl. Acid Res., 11:2325, 1983).
- a cDNA expression library such as lambda gt11, can be screened indirectly for FHF-2 peptides having at least one epitope, using antibodies specific for FHF-2.
- Such antibodies can be either polyclonally or monoclonally derived and used to detect expression product indicative of the presence of FHF-2 cDNA.
- DNA sequences encoding FHF-2 can be expressed in vitro by DNA transfer into a suitable host cell.
- “Host cells” are cells in which a vector can be propagated and its DNA expressed. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term “host cell” is used. Methods of stable transfer, meaning that the foreign DNA is continuously maintained in the host, are known in the art.
- the FHF-2 polynucleotide sequences may be inserted into a recombinant expression vector.
- recombinant expression vector refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of the FHF-2 genetic sequences.
- Such expression vectors contain a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host.
- the expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells.
- Vectors suitable for use in the present invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg, et al., Gene, 56:125, 1987), the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, J. Biol. Chem., 263:3521, 1988) and baculovirus-derived vectors for expression in insect cells.
- the DNA segment can be present in the vector operably linked to regulatory elements, for example, a promoter (e.g., T7, metallothionein 1, or polyhedrin promoters).
- Polynucleotide sequences encoding FHF-2 can be expressed in either prokaryotes or eukaryotes.
- Hosts can include microbial, yeast, insect and mammalian organisms. Methods of expressing DNA sequences having eukaryotic or viral sequences in prokaryotes are well known in the art.
- Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art. Such vectors are used to incorporate DNA sequences of the invention.
- Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art.
- the host is prokaryotic, such as E. coli
- competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl 2 method using procedures well known in the art.
- MgCl 2 or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell if desired.
- Eukaryotic cells can also be cotransformed with DNA sequences encoding the FHF-2 of the invention, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene.
- Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein.
- a eukaryotic viral vector such as simian virus 40 (SV40) or bovine papilloma virus
- SV40 simian virus 40
- bovine papilloma virus bovine papilloma virus
- Isolation and purification of microbial expressed polypeptide, or fragments thereof, provided by the invention may be carried out by conventional means including preparative chromatography and immunological separations involving monoclonal or polyclonal antibodies.
- the FHF-2 polypeptides of the invention can also be used to produce antibodies which are immunoreactive or bind to epitopes of the FHF-2 polypeptides.
- Antibody which consists essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations are provided.
- Monoclonal antibodies are made from antigen containing fragments of the protein by methods well known in the art (Kohler, et al., Nature, 256:495, 1975; Current Protocols in Molecular Biology , Ausubel, et al., ed., 1989).
- antibody as used in this invention includes intact molecules as well as fragments thereof, such as Fab, F(ab′) 2 , and Fv which are capable of binding the epitopic determinant. These antibody fragments retain some ability to selectively bind with its antigen or receptor and are defined as follows:
- epitopic determinants means any antigenic determinant on an antigen to which the paratope of an antibody binds.
- Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
- Antibodies which bind to the FHF-2 polypeptide of the invention can be prepared using an intact polypeptide or fragments containing small peptides of interest as the immunizing antigen.
- the polypeptide or a peptide used to immunize an animal can be derived from translated cDNA (see for example, EXAMPLE 4) or chemical synthesis which can be conjugated to a carrier protein, if desired.
- carrier protein e.g., EXAMPLE 4
- Such commonly used carriers which are chemically coupled to the peptide include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid.
- KLH keyhole limpet hemocyanin
- BSA bovine serum albumin
- the coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).
- polyclonal or monoclonal antibodies can be further purified, for example, by binding to and elution from a matrix to which the polypeptide or a peptide to which the antibodies were raised is bound.
- a matrix to which the polypeptide or a peptide to which the antibodies were raised is bound.
- Those of skill in the art will know of various techniques common in the immunology arts for purification and/or concentration of polyclonal antibodies, as well as monoclonal antibodies (See for example, Coligan, et al., Unit 9, Current Protocols in Immunology , Wiley Interscience, 1994, incorporated by reference).
- an anti-idiotypic monoclonal antibody made to a first monoclonal antibody will have a binding domain in the hypervariable region which is the “image” of the epitope bound by the first monoclonal antibody.
- cell-proliferative disorder denotes malignant as well as non-malignant cell populations which often appear to differ from the surrounding tissue both morphologically and genotypically. Malignant cells (i.e. cancer) develop as a result of a multistep process.
- the FHF-2 polynucleotide that is an antisense molecule is useful in treating malignancies of the various organ systems, particularly, for example, cells in the central nervous system, including neural tissue, heart, and cells of the eye.
- any disorder which is etiologically linked to altered expression of FHF-2 could be considered susceptible to treatment with a FHF-2 suppressing reagent.
- One such disorder is a malignant cell proliferative disorder, for example.
- an antibody or nucleic acid probe specific for FHF-2 may be used to detect FHF-2 polypeptide (using antibody) or polynucleotide (using nucleic acid probe) in biological tissues or fluids.
- the invention provides a method for detecting a cell proliferative disorder of cardiac tissue or neural tissue, for example, which comprises contacting an anti-FHF-2 antibody or nucleic acid probe with a cell suspected of having a FHF-2 associated disorder and detecting binding of FHF-2 antigen or mRNA to the antibody or nucleic acid probe, respectively.
- the antibody or nucleic acid probe reactive with FHF-2 is preferably labeled with a compound which allows detection of binding to FHF-2. Any specimen containing a detectable amount of antigen can be used.
- a preferred sample of this invention is neural tissue or heart tissue.
- the level of FHF-2 in the suspect cell can be compared with the level in a normal cell to determine whether the subject has a FHF-2-associated cell proliferative disorder.
- the subject is human.
- PCR polymerase chain reaction
- LAT ligated activated transcription
- NASBA nucleic acid sequence-based amplification
- the antibodies of the invention can be used in any subject in which it is desirable to administer in vitro or in vivo immunodiagnosis or immunotherapy.
- the antibodies of the invention are suited for use, for example, in immunoassays in which they can be utilized in liquid phase or bound to a solid phase carrier.
- the antibodies in these immunoassays can be detectably labeled in various ways.
- types of immunoassays which can utilize antibodies of the invention are competitive and non-competitive immunoassays in either a direct or indirect format. Examples of such immunoassays are the radioimmunoassay (RIA) and the sandwich (immunometric) assay.
- Detection of the antigens using the antibodies of the invention can be done utilizing immunoassays which are run in either the forward, reverse, or simultaneous modes, including immunohistochemical assays on physiological samples. Those of skill in the art will know, or can readily discern, other immunoassay formats without undue experimentation.
- the antibodies of the invention can be bound to many different carriers and used to detect the presence of an antigen comprising the polypeptide of the invention.
- carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and magnetite.
- the nature of the carrier can be either soluble or insoluble for purposes of the invention. Those skilled in the art will know of other suitable carriers for binding antibodies, or will be able to ascertain such, using routine experimentation.
- labels and methods of labeling known to those of ordinary skill in the art.
- Examples of the types of labels which can be used in the present invention include enzymes, radioisotopes, fluorescent compounds, colloidal metals, chemiluminescent compounds, phosphorescent compounds, and bioluminescent compounds.
- Those of ordinary skill in the art will know of other suitable labels for binding to the antibody, or will be able to ascertain such, using routine experimentation.
- Another technique which may also result in greater sensitivity consists of coupling the antibodies to low molecular weight haptens. These haptens can then be specifically detected by means of a second reaction. For example, it is common to use such haptens as biotin, which reacts with avidin, or dinitrophenyl, puridoxal, and fluorescein, which can react with specific antihapten antibodies.
- the detectably labeled antibody is given a dose which is diagnostically effective.
- diagnostically effective means that the amount of detectably labeled monoclonal antibody is administered in sufficient quantity to enable detection of the site having the antigen comprising a polypeptide of the invention for which the monoclonal antibodies are specific.
- the concentration of detectably labeled monoclonal antibody which is administered should be sufficient such that the binding to those cells having the polypeptide is detectable compared to the background. Further, it is desirable that the detectably labeled monoclonal antibody be rapidly cleared from the circulatory system in order to give the best target-to-background signal ratio.
- the dosage of detectably labeled monoclonal antibody for in vivo diagnosis will vary depending on such factors as age, sex, and extent of disease of the individual. Such dosages may vary, for example, depending on whether multiple injections are given, antigenic burden, and other factors known to those of skill in the art.
- a radioisotope used for in vivo imaging will lack a particle emission, but produce a large number of photons in the 140-250 keV range, which may readily be detected by conventional gamma cameras.
- radioisotopes may be bound to immunoglobulin either directly or indirectly by using an intermediate functional group.
- Intermediate functional groups which often are used to bind radioisotopes which exist as metallic ions to immunoglobulins are the bifunctional chelating agents such as diethylenetriaminepentacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA) and similar molecules.
- DTPA diethylenetriaminepentacetic acid
- EDTA ethylenediaminetetraacetic acid
- metallic ions which can be bound to the monoclonal antibodies of the invention are 111 In, 97 Ru 67 Ga 68 Ga 72 As 89 Zr, and 201 Tl.
- the monoclonal antibodies of the invention can also be labeled with a paramagnetic isotope for purposes of in vivo diagnosis, as in magnetic resonance imaging (MRI) or electron spin resonance (ESR).
- MRI magnetic resonance imaging
- ESR electron spin resonance
- any conventional method for visualizing diagnostic imaging can be utilized.
- gamma and positron emitting radioisotopes are used for camera imaging and paramagnetic isotopes for MRI.
- Elements which are particularly useful in such techniques include 157 Gd, 55 Mn, 162 Dy, 52 Cr, and 56 Fe.
- the monoclonal antibodies or polynucleotides of the invention can be used in vitro and in vivo to monitor the course of amelioration of a FHF-2-associated disease in a subject.
- a particular therapeutic regimen aimed at ameliorating the FHF-2-associated disease is effective.
- the term “ameliorate” denotes a lessening of the detrimental effect of the FHF-2-associated disease in the subject receiving therapy.
- the present invention identifies a nucleotide sequence that can be expressed in an altered manner as compared to expression in a normal cell, therefore it is possible to design appropriate therapeutic or diagnostic techniques directed to this sequence.
- Detection of elevated levels of FHF-2 expression is accomplished by hybridization of nucleic acids isolated from a cell suspected of having an FHF-2 associated proliferative disorder with an FHF-2 polynucleotide of the invention. Analyses, such as Northern Blot analysis, are utilized to quantitate expression of FHF-2. Other standard nucleic acid detection techniques will be known to those of skill in the art.
- Treatment of an FHF-2 associated cell proliferative disorder include modulation of FHF-2 gene expression and FHF-2 activity.
- modulate envisions the suppression of expression of FHF-2 when it is over-expressed, or augmentation of FHF-2 expression when it is under-expressed.
- nucleic acid sequences that interfere with FHF-2 expression at the translational level can be used. This approach utilizes, for example, antisense nucleic acid, ribozymes, or triplex agents to block transcription or translation of a specific FHF-2 mRNA, either by masking that mRNA with an antisense nucleic acid or triplex agent, or by cleaving it with a ribozyme.
- disorders include neurodegenerative diseases, for example.
- Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule (Weintraub, Scientific American, 262:40, 1990). In the cell, the antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule. The antisense nucleic acids interfere with the translation of the mRNA, since the cell will not translate a mRNA that is double-stranded. Antisense oligomers of about 15 nucleotides are preferred, since they are easily synthesized and are less likely to cause problems than larger molecules when introduced into the target FHF-2-producing cell. The use of antisense methods to inhibit the in vitro translation of genes is well known in the art (Marcus-Sakura, AnalBiochem., 172:289, 1988).
- triplex strategy Use of an oligonucleotide to stall transcription is known as the triplex strategy since the oligomer winds around double-helical DNA, forming a three-strand helix. Therefore, these triplex compounds can be designed to recognize a unique site on a chosen gene (Maher, et al., Antisense Res. and Dev., 1(3):227, 1991; Helene, C., Anticancer Drug Design, 6(6):569, 1991).
- Ribozymes are RNA molecules possessing the ability to specifically cleave other single-stranded RNA in a manner analogous to DNA restriction endonucleases. Through the modification of nucleotide sequences which encode these RNAs, it is possible to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, J. Amer. Med. Assn., 260:3030, 1988). A major advantage of this approach is that, because they are sequence-specific, only mRNAs with particular sequences are inactivated.
- ribozymes There are two basic types of ribozymes namely, tetrahymena-type (Hasselhoff, Nature, 334:585, 1988) and “hammerhead”-type. Tetrahymena-type ribozymes recognize sequences which are four bases in length, while “hammerhead”-type ribozymes recognize base sequences 11-18 bases in length. The longer the recognition sequence, the greater the likelihood that the sequence will occur exclusively in the target mRNA species. Consequently, hammerhead-type ribozymes are preferable to tetrahymena-type ribozymes for inactivating a specific mRNA species and 18-based recognition sequences are preferable to shorter recognition sequences.
- the present invention also provides gene therapy for the treatment of cell proliferative or immunologic disorders which are mediated by FHF-2 protein. Such therapy would achieve its therapeutic effect by introduction of the FHF-2 antisense polynucleotide into cells having the proliferative disorder. Delivery of antisense FHF-2 polynucleotide can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system. Especially preferred for therapeutic delivery of antisense sequences is the use of targeted liposomes.
- RNA virus such as a retrovirus
- retroviral vector is a derivative of a murine or avian retrovirus.
- retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV).
- MoMuLV Moloney murine leukemia virus
- HaMuSV Harvey murine sarcoma virus
- MuMTV murine mammary tumor virus
- RSV Rous Sarcoma Virus
- GaLV gibbon ape leukemia virus
- retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. By inserting a FHF-2 sequence of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector is now target specific. Retroviral vectors can be made target specific by attaching, for example, a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody to target the retroviral vector.
- helper cell lines that contain plasmids encoding all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR. These plasmids are missing a nucleotide sequence which enables the packaging mechanism to recognize an RNA transcript for e-ncapsidation.
- Helper cell lines which have deletions of the packaging signal include, but are not limited to ⁇ 2, PA317 and PA 12, for example. These cell lines produce empty virions, since no genome is packaged. If a retroviral vector is introduced into such cells in which the packaging signal is intact, but the structural genes are replaced by other genes of interest, the vector can be packaged and vector virion produced.
- NIH 3T3 or other tissue culture cells can be directly transfected with plasmids encoding the retroviral structural genes gag, pol and env, by conventional calcium phosphate transfection. These cells are then transfected with the vector plasmid containing the genes of interest. The resulting cells release the retroviral vector into the culture medium.
- colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
- the preferred colloidal system of this invention is a liposome.
- Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. It has been shown that large unilamellar vesicles (LUV). which range in size from 0.2-4.0 ⁇ m can encapsulate a substantial percentage of an aqueous buffer containing large macro-molecules.
- LUV large unilamellar vesicles
- RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., Trends Biochem. Sci., 6:77, 1981).
- liposomes In addition to mammalian cells, liposomes have been used for delivery of polynucleotides in plant, yeast and bacterial cells.
- a liposome In order for a liposome to be an efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the genes of interest at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information (Mannino, et al., Biotechniques, 6:682, 1988).
- the composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used.
- the physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.
- lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Particularly useful are d-iacylphosphatidylglycerols, where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated.
- Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.
- the targeting of liposomes can be classified based on anatomical and mechanistic factors.
- Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and organelle-specific.
- Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system (RES) in organs which contain sinusoidal capillaries.
- RES reticulo-endothelial system
- Active targeting involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.
- a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein
- the surface of the targeted delivery system may be modified in a variety of ways.
- lipid groups can be incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer.
- Various linking groups can be used for joining the lipid chains to the targeting ligand.
- FHF-2 Due to the expression of FHF-2 in heart, eye, and brain, or neural tissue, there are a variety of applications using the polypeptide, polynucleotide, and antibodies of the invention, related to these tissues. Such applications include treatment of cell proliferative and immunologic disorders involving these and other tissues. In addition, FHF-2 may be useful in various gene therapy procedures.
- the identification of a novel member of the FGF family provides a useful tool for diagnosis, prognosis and therapeutic strategies associated with FHF-2 mediated disorders.
- Measurement of FHF-2 levels using anti-FHF-2 antibodies is useful diagnostic for following the progression or recovery from diseases of the nervous system, including: cancer, stroke, neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease, retinal diseases such as retinitis p-igmentosa, or viral encephalitis.
- the presence of high levels of FHF-2 in the central nervous system suggests that the observed low level of FHF-2 in a number of peripheral tissues could reflect FHF-2 in peripheral nerve, and therefore measurement of FHF-2 levels using anti-FHF-2 antibodies could be diagnostic for peripheral neuropathy.
- the presence of high levels of FHF-2 in the heart suggests that measurement of FHF-2 levels using anti-FHF-2 antibodies is useful as a diagnostic for myocardial infarction, viral endocarditis, or other cardiac disorders.
- FHF-2 likely has mitogenic and/or cell survival activity, therefore FHF-2 or an analogue that mimics FHF-2 action could be used to promote tissue repair or replacement.
- FHF-2 in the CNS suggests such a therapeutic role in diseases of the nervous system, including: stroke, neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease, or in retinal degenerative diseases such as retinitis pigmentosa or macular degeneration, or in peripheral neuropathies.
- the presence of high levels of FHF-2 in the heart suggests that FHF-2 or an analogue of FHF-2 could be used to accelerate recovery from myocardial infarction or could promote increased cardiac output by increasing heart muscle.
- blocking FHF-2 action either with anti-FHF-2 antibodies or with an FHF-2 antagonist might slow or ameliorate diseases in which excess cell growth is pathological, most obviously cancer.
- an adult human retina cDNA library constructed in lambda gt10 (Nathans, et al., Science, 232: 193, 1986) was amplified, and the cDNA inserts were excised en mass by cleavage with EcoR I and purified free of the vector by agarose gel electrophoresis.
- a synthetic oligonucleotide containing an EcoR I site at its 5′ end and six random nucleotides at its 3′ end (5′ GACGAGATATTAGAATTCTACTCGNNNN) (SEQ ID NO:3) was used to prime two sequential rounds of DNA synthesis in the presence of the Klenow fragment of E. coli DNA polymerase.
- the resulting duplex molecules were amplified using the polymerase chain reaction (PCR) with a primer corresponding to the unique 5′ flanking sequence (5′ CCCCCCCCCGACGAGATATTAGAATTCTACTCG) (SEQ ID NO:4).
- PCR polymerase chain reaction
- SEQ ID NO:4 a primer corresponding to the unique 5′ flanking sequence
- These PCR products representing a random sampling of the original cDNA inserts, were cleaved with EcoR I, size fractionated by preparative agarose gel electrophoresis to include only segments of approximately 500 bp in length, and cloned into lambda gt10.
- FHF-1 Fibroblast Growth Factor Homologous Factor-1 (FHF-1) and Methods of Use”, Nathans et al., filed May 12, 1995).
- a search of partial cDNA sequences (‘ e xpressed s equence t ags’, ESTs) in the public databases revealed a human adult testis cDNA fragment (NCBI ID 28057, EST ID EST06895, Genbank ID T09003; Adams, et al., Nature Genetics, 4: 373, 1993) with strong homology to FHF-1, but only weak homology to other members of the FGF family.
- the homology between this EST and other members of the FGF family is sufficiently low that no indication of that homology was noted in the description associated with the clone in Genbank or in the publication describing the EST sequence (Adams, et al., supra, 1993).
- this fragment was amplified by PCR from a human retina cDNA library and used as a probe to isolate multiple independent cDNA clones from that library, including two that encompass the entire open reading frame and from which complete nucleotide sequences were determined. This sequence was named FHF-2.
- FIG. 1 shows the sequence of human FHF-2 deduced from the nucleotide sequences of two independent human retina cDNA clones.
- the primary translation product of human FHF-2 is predicted to be 245 amino acids in length.
- the human FHF-2 inititiator methionine codon shown in FIG. 1 at position 352-354 corresponds to the location of the initiator methionine codon of FHF-1 when the two sequences are aligned; a good consensus ribosome binding site (TGGCCATGG; Kozak, Nucleic Acids Res., 15: 8125, 1987) (SEQ ID NO:5) is found at this position.
- the next methionine codon within the open reading frame is encountered 124 codons 3′ of the putative initiator methionine codon.
- the amino-terminus of the primary translation product of FHF-2 does not conform to the consensus sequence for a signal peptide to direct cotranslational insertion across the endoplasmic reticulum membrane.
- the FHF-2 sequence has one potential asn-X-ser/thr site for asparagine-linked glycosylation four amino acids from the carboxy-terminus.
- FIG. 2 Alignment of FHF-2 with the other known members of the FGF family is shown in FIG. 2 and a dendrogram showing the degree of amino acid similarity is shown in FIG. 3 .
- the most homologous FGF family member is FGF-9 which shows 28% amino acid identity with FHF-2 when aligned with 6 gaps. Note that in the central region of each polypeptide, all FGF family members, including FHF-2, share 11 invariant amino acids.
- the chromosomal location of FHF-2 was determined by probing a Southern blot containing restriction enzyme digested DNA derived from a panel of 24 human-mouse and human-hamster cell lines, each containing a different human chromosome (Oncor, Gaithersburg, Md.). As seen in FIG. 4 , hybridization of the human FHF-2 probe to human, mouse, and hamster genomic DNA produces distinct hybridizing fragment sizes. The human-specific hybridization pattern is seen only in the lane corresponding to the hybrid cell line carrying the human X-chromosome.
- the complete open reading frame was inserted into the eukaryotic expression vector pCIS (Gorman, et al., DNA Protein Eng. Tech., 2: 3, 1990).
- the region immediately 5′ of the initiator methionine coding was converted to an optimal ribosome binding site (CCACCATGG) (SEQ ID NO:5) by cutting the FHF-2 coding region at the initiator methionine with Nco 1 (which recognizes CCATGG) and ligating to the expression vector.
- FIG. 5 shows that cells transfected with FHF-2 synthesize a single polypeptide with an apparent molecular mass of 30 kD that is not produced by untransfected cells or by cells transfected with an unrelated construct. This polypeptide corresponds closely to the predicted molecular mass of the primary translation product, 27.6 kD.
- FIG. 5 also shows that cells transfected with a human growth hormone (hGH) expression plasmid efficiently secrete hGH, whereas FHF-2 accumulates within the transfected cells and fails to be secreted in detectable quantities.
- hGH human growth hormone
- FHF-2 mRNA was analyzed for tissue distribution.
- RNase protection analysis was performed on total RNA from mouse brain, eye, heart, kidney, liver, lung, spleen, and testis, as well as a yeast tRNA negative control.
- the probe used was derived from a segment of the mouse FHF-2 gene isolated by hybridization with the full-length human FHF-2 cDNA. As seen in FIG. 6 , the highest levels of FHF-2 expression are in the brain, eye, and heart. Very low levels of FHF-2 expression were detected in all of the other tisssues on a longer exposure of the autoradiogram.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A novel growth factor, fibroblast growth factor homologous factor-2 (FHF-2) polypeptide, the polynucleotide sequence encoding FHF-2 and the deduced amino acid sequence are disclosed. Also disclosed are diagnostic and therapeutic methods of using the FHF-2 polypeptide and polynucleotide sequences and antibodies which specifically bind to FHF-2.
Description
- Under 35 USC § 120, this application is a continuation application of U.S. application Ser. No. 10/192,988 filed Jul. 10, 2002; which is a continuation of U.S. application Ser. No. 09/261,007 filed Mar. 2, 1999; which is a divisional of U.S. application Ser. No. 08/438,439 filed May 12, 1995 and issued as U.S. Pat. No. 5,876,967. This disclosure of the prior applications is considered part of and is incorporated by reference in the disclosure of this application.
- 1. Field of the Invention
- The invention relates generally to growth factors and specifically to a novel member of the fibroblast growth factor family, denoted fibroblast growth factor homologous factor-2 (FHF-2) and the polynucleotide encoding FHF-2.
- 2. Description of Related Art
- The fibroblast growth factor family encompasses a group of structurally related proteins with a wide range of growth promoting, survival, and/or differentiation activities in vivo and in vitro (reviewed in Baird, A., and Gospodarowicz, D. Ann N.Y. Acad. Sci. 638: 1, 1991; Eckenstein, F. P., J. Neurobiology 25: 1467, 1994; Mason, I. J. Cell 78: 547, 1994). As of December 1994, nine members of this family had been characterized by molecular cloning. The first two members of the family to be characterized, acidic fibroblast growth factor (aFGF/FGF-1) and basic fibroblast growth factor (bFGF/FGF-2), have been found in numerous tissues, including for example brain, eye, kidney, placenta, and adrenal (Jaye et al., Science 233: 541, 1986; Abraham et al., Science 233: 545, 1986). These factors have been shown to be potent mitogens and survival factors for a variety of mesoderm and neurectoderm-derived tissues, including fibroblasts, endothelial cells, hippocampal and cerebral cortical neurons, and astroglia (Burgess, W. H. and Maciag, T. Ann. Rev. Biochemistry 58: 575, 1989). Additional members of the FGF family include: int-2/FGF-3, identified as one of the frequent sites of integration of the mouse mammary tumor virus, and therefore a presumptive oncogenic factor (Smith et al., EMBO J. 7: 1013, 1988); FGF-4 (Delli-Bovi et al., Cell 50: 729, 1987) and FGF-5 (Zhan et al., Mol. Cell Biol. 8, 3487, 1988) as transforming genes in the NIH 3T3 transfection assay; FGF-6, isolated by molecular cloning based on its homology to FGF-4 (Marics et al., Oncogene 4: 335 (1989); keratinocyte growth factor/ FGF-7, identified as a mitogen for keratinocytes (Finch et al., Science 245: 752.1989); FGF-8 as an androgen-induced mitogen for mammary carcinoma cells (Tanaka et al., Proc. Natl. Acad. Sci. USA 89: 8928, 1992); and FGF-9 as a mitogen for primary astrocytes (Miyamoto et al., Mol. Cell Biol. 13: 4251, 1993). Several of the FGFs, including aFGF and bFGF, lack a classical signal sequence; the mechanism by which they are secreted is not known.
- All members of the FGF family share approximately 25% or more amino acid sequence identity, a degree of homology indicating that they are likely to share nearly identical three-dimensional structures. Support for this inference comes from a comparison of the three-dimensional structures of bFGF and interleukin 1-beta determined by x-ray diffraction (Eriksson et al., Proc. Natl. Acad. Sci USA 88: 3441, 1991; Zhang et al., Proc. Natl. Acad. Sci USA 88: 3446. 1991; Ago et al., J. Biochem. 110: 360, 1991). Although these proteins share only 10% amino acid identity, the alpha carbon backbones of the two crystal structures can be superimposed with a root-mean square deviation of less than 2 angstroms (Zhang et al., Proc. Natl. Acad. Sci USA 88: 3446, 1991). Both proteins consist almost entirely of beta-sheets, which form a barrel composed of three copies of a four-stranded beta-meander motif. The likely heparin- and receptor-binding regions are located on nearby regions on one face of the protein.
- aFGF, bFGF, and FGF-7/KGF have been shown to exert some or all of their biological activity through high affinity binding to cell surface tyrosine kinase receptors (e.g., Lee, P. L. et al., Science 245: 57, 1989; reviewed in Johnson, D. E. and Williams, L. T., Adv. Cancer Res. 60: 1, 1993). Many members of the FGF family also bind tightly to heparin, and a terniary complex of heparin, FGF, and transmembrane receptor may be the biologically relevant signalling species. Thus far four different genes have been identified that encode receptors for FGF family members. Recent work has shown that receptor diversity is increased by differential mRNA splicing within the extracellular ligand binding domain, with the result that multiple receptor isoforms with different ligand binding properties can be encoded by the same gene (Johnson, D. E. and Williams, L. T., Adv. Cancer Res. 60: 1, 1993). In tissue culture systems, the binding of aFGF or bFGF to its cell surface receptor activates phospholipase C-gamma (Burgess, W. H. et al., Mol. Cell Biol. 10: 4770, 1990), a pathway known to integrate a variety of mitogenic signals.
- Identification and characterization of new members of the FGF family will provide insights into the mechanisms by which cells and organs control their growth, survival, senescence, differentiation, and recovery from injury.
- The present invention provides a cell growth, survival and differentiation factor, FHF-2, and a polynucleotide sequence which encodes the factor. This factor is involved in the growth, survival, and or differentiation of cells within the central nervous system (CNS) and in the heart.
- The invention provides a method for detecting alterations in FHF-2 gene expression which are diagnostic of neurodegenerative, neoplastic, or cardiac disorders. In another embodiment, the invention provides a method for treating a neurodegenerative, neoplastic or cardiac disorder by enhancing or suppressing the expression or activity of FHF-2.
-
FIG. 1 shows the nucleotide and predicted amino acid sequence of human FHF-2 (SEQ ID NO:1 and SEQ ID NO:2). -
FIGS. 2A and B show an alignment of the amino acid sequence of human FHF-2 and each of the published nine members of the FGF family. Conserved residues are highlighted. The FGF family members are: aFGF/FGF-1 (SEQ ID NO:22) (Jaye et al., Science 233: 541, 1986), bFGF/FGF-2 (SEQ ID NO:24) (Abraham et al., Science 233: 545, 1986), int-2/FGF-3 (SEQ ID NO: 17) (Smith et al., EMBO J. 7: 1013, 1988), FGF-4 (SEQ ID NO:19) (Delli-Bovi et al., Cell 50: 729, 1987), FGF-5 (SEQ ID NO: 18) (Zhan et al., Mol. Cell Biol. 8, 3487, 1988), FGF-6 (SEQ ID NO:20) (Marics et al., Oncogene 4: 335, 1989); keratinocyte growth factor/FGF-7 (SEQ ID NO:23) (Finch et al.. Science 245: 752. 1989), FGF-8 (SEQ ID NO: 16) (Tanaka et al., Proc. Nati. Acad. Sci. USA 89: 8928, 1992), and FGF-9 (SEQ ID NO:21) (Miyamoto et al.. Mol. Cell Biol. 13: 4251, 1993). -
FIG. 3 shows a dendrogram in which the length of each path connecting any pair of FGF family members is proportional to the degree of amino acid sequence divergence of that pair. -
FIG. 4 shows the location of the gene encoding FHF-2 on the human X-chromosome. A Southern blot was prepared from DNA derived from mouse-human or hamster-human hybrid cell lines, each of which contains a single human chromosome, indicated above each lane. The human specific hybridization is found on the X-chromosome. -
FIG. 5 shows the production of FHF-2 in transfected human embryonic kidney cells. Proteins were labeled biosynthetically with 35S-methionine and resolved by SDS-polyacrylamide gel electrophoresis.Lanes lanes Lanes lanes lanes lanes -
FIG. 6 shows the tissue specificity of FHF-2 expression. Ten micrograms of total RNA from the indicated mouse tissues was prepared (Chomczinski & Sacchi. Anal. Biochem. 162: 156, 1987) and used for RNAse protection (Ausabel et al., Current Protocols in Molecular Biology; New York: Wiley Interscience, 1987) with a mouse FHF-2 antisense probe that spanned 197 bases of the most 3′ coding region exon and the adjacent upstream 335 bases of intron sequence. RNAse protection at the size expected for the 197 base exon region of the probe (arrowheads) was observed with RNA from brain, eye, and heart. A longer exposure reveals barely visible bands in all of the other tissues but not in the tRNA control sample. - The present invention provides a growth factor, FHF-2, and a polynucleotide sequence encoding FHF-2. FHF-2 is expressed at high levels in brain and heart tissues. In one embodiment, the invention provides a method for detection of a cell proliferative or immunologic disorder of central nervous system or cardiac tissue origin which is associated with FHF-2 expression or function. In another embodiment, the invention provides a method for treating a cell proliferative or immunologic disorder by using an agent which suppresses or enhances FHF-2 expression or activity.
- The structural homology between the FHF-2 protein of this invention and the members of the FGF family, indicates that FHF-2 is a new member of the family of growth factors. Based on the known activities of many of the other members, it can be expected that FHF-2 will also possess biological activities that will make it useful as a diagnostic and therapeutic reagent.
- Many growth factors have expression patterns or possess activities that relate to the function of the nervous system. For example, one growth factor in the TGF family, namely GDNF, has been shown to be a potent neurotrophic factor that can promote the survival of dopaminergic neurons (Lin, et al., Science, 260:1130). Another family member, namely dorsalin-1, is capable of promoting the differentiation of neural crest cells (Basler, et al., Cell, 73:687, 1993). The inhibins and activins have been shown to be expressed in the brain (Meunier, et al., Proc. Nat'l. Acad. Sci., USA, 85:247,1988; Sawchenko, et al., Nature, 334:615, 1988), and activin has been shown to be capable of functioning as a nerve cell survival molecule (Schubert, et al., Nature, 344:868. 1990). Another TGF family member, namely GDF-1, is nervous system-specific in its expression pattern (Lee, Proc. Nat'l. Acad. Sci., USA, 88:4250, 1991), and certain other family members, such as Vgr-1 (Lyons, et al., Proc. Nat'l. Acad. Sci., USA, 86:4554, 1989; Jones, et al., Development, 111:581, 1991), OP-1 (Ozkaynak, et al., J. Biol. Chem., 267:25220, 1992), and BMP-4 (Jones, et al., Development, 111:531, 1991), are also known to be expressed in the nervous system.
- The expression of FHF-2 in brain and eye suggests that FHF-2 may also possess activities that relate to the function of the nervous system. The known neurotrophic activities of other members of this family and the expression of FHF-2 in muscle suggest that one activity of FHF-2 may be as a trophic factor for motor neurons. Alternatively, FHF-2 may have neurotrophic activities for other neuronal populations. Hence, FHF-2 may have in vitro and in vivo applications in the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis, or in maintaining cells or tissues in culture prior to transplantation.
- Growth factors have also been shown to inhibit the differentiation of myoblasts in culture (Massague, et al., Proc. Natl. Acad Sci., USA 83:8206, 1986). Moreover, because myoblast cells may be used as a vehicle for delivering genes to muscle for gene therapy, the properties of FHF-2, namely the elevated expression in heart tissue (i.e., muscle), could be exploited for maintaining cells prior to transplantation or for enhancing the efficiency of the fusion process.
- In a first embodiment, the invention provides substantially pure fibroblast growth factor homologous factor-2 (FHF-2) characterized by having a molecular weight of about 30 kD as determined by reducing SDS-PAGE and having essentially the amino acid sequence of SEQ ID NO:2. The term “substantially pure” as used herein refers to FHF-2 which is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. One skilled in the art can purify FHF-2 using standard techniques for protein purification. The substantially pure polypeptide will yield a single major band on a non-reducing polyacrylamide gel. The purity of the FHF-2 polypeptide can also be determined by amino-terminal amino acid sequence analysis. FHF-2 polypeptide includes functional fragments of the polypeptide, as long as the activity of FHF-2 remains. Smaller peptides containing the biological activity of FHF-2 are included in the invention.
- The invention provides polynucleotides encoding the FHF-2 protein. These polynucleotides include DNA, cDNA and RNA sequences which encode FHF-2. It is understood that all polynucleotides encoding all or a portion of FHF-2 are also included herein, as long as they encode a polypeptide with FHF-2 activity. Such polynucleotides include naturally occurring, synthetic, and intentionally manipulated polynucleotides. For example, FHF-2 polynucleotide may be subjected to site-directed mutagenesis. The polynucleotide sequence for FHF-2 also includes antisense sequences. The polynucleotides of the invention include sequences that are degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the invention as long as the amino acid sequence of FHF-2 polypeptide encoded by the nucleotide sequence is functionally unchanged.
- Specifically disclosed herein is a DNA sequence encoding the human FHF-2 gene. The sequence contains an open reading frame encoding a
polypeptide 245 amino acids in length. The human FHF-2 inititiator methionine codon shown inFIG. 1 at position 352-354 corresponds to the location of the initiator methionine codon of another FGF family member, FHF-1, when the two sequences are aligned; a good consensus ribosome binding site (-TGGCCATGG; Kozak, Nucleic Acids Res., 15: 8125, 1987) is found at this position. The next methionine codon within the open reading frame is encountered 124codons 3′ of the putative initiator methionine codon. As observed for aFGF and bFGF, the amino-terminus of the primary translation product of FHF-2 does not conform to the consensus sequence for a signal peptide to direct cotranslational insertion across the endoplasmic reticulum membrane. The FHF-2 sequence has one potential asn-X-ser/thr site for asparagine-linked glycosylation four amino acids from the carboxy-terminus. Preferably, the human FHF-2 nucleotide sequence is SEQ ID NO:1 and the deduced amino acid sequence is probably SEQ ID NO:2. - The polynucleotide encoding FHF-2 includes SEQ ID NO:1 as well as nucleic acid sequences complementary to SEQ ID NO:1. A complementary sequence may include an antisense nucleotide. When the sequence is RNA, the deoxynucleotides A, G, C, and T of SEQ ID NO:1 is replaced by ribonucleotides A, G, C, and U, respectively. Also included in the invention are fragments of the above-described nucleic acid sequences that are at least 15 bases in length, which is sufficient to permit the fragment to selectively hybridize to DNA that encodes the protein of SEQ ID NO:2 under physiological conditions. Specifically, the fragments should hybridize to DNA encoding FHF-2 protein under stringent conditions.
- The most homologous FGF family member is FGF-9, which shares 28% amino acid identity with FHF-2, when aligned with 6 gaps. Minor modifications of the FHF-2 primary amino acid sequence may result in proteins which have substantially equivalent activity as compared to the FHF-2 polypeptide described herein. Such proteins include those as defined by the term “having essentially the amino acid sequence of SEQ ID NO.2”. Such modifications may be deliberate, as by site-directed mutagenesis, or may be spontaneous. All of the polypeptides produced by these modifications are included herein as long as the biological activity of FHF-2 still exists. Further, deletion of one or more amino acids can also result in a modification of the structure of the resultant molecule without significantly altering its biological activity. This can lead to the development of a smaller active molecule which would have broader utility. For example, one can remove amino or carboxy terminal amino acids which are not required for FHF-2 biological activity.
- The nucleotide sequence encoding the FHF-2 polypeptide of the invention includes the disclosed sequence (SEQ ID NO:2), and conservative variations thereof. The term “conservative variation” as used herein denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine, and the like. The term “conservative variation” also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.
- DNA sequences of the invention can be obtained by several methods. For example, the DNA can be isolated using hybridization techniques which are well known in the art. These include, but are not limited to: 1) hybridization of genomic or cDNA libraries with probes to detect homologous nucleotide sequences, 2) polymerase chain reaction (PCR) on genomic DNA or cDNA using primers capable of annealing to the DNA sequence of interest, and 3) antibody screening of expression libraries to detect cloned DNA fragments with shared structural features.
- Preferably the FHF-2 polynucleotide of the invention is derived from a mammalian organism, and most preferably from human. Screening procedures which rely on nucleic acid hybridization make it possible to isolate any gene sequence from any organism, provided the appropriate probe is available. Oligonucleotide probes, which correspond to a part of the sequence encoding the protein in question, can be synthesized chemically. This requires that short, oligopeptide stretches of amino acid sequence must be known. The DNA sequence encoding the protein can be deduced from the genetic code, however, the degeneracy of the code must be taken into account. It is possible to perform a mixed addition reaction when the sequence is degenerate. This includes a heterogeneous mixture of denatured double-stranded DNA. For such screening, hybridization is preferably performed on either single-stranded DNA or denatured double-stranded DNA. Hybridization is particularly useful in the detection of cDNA clones derived from sources where an extremely low amount of mRNA sequences relating to the polypeptide of interest are present. In other words, by using stringent hybridization conditions directed to avoid non-specific binding, it is possible, for example, to allow the autoradiographic visualization of a specific cDNA clone by the hybridization of the target DNA to that single probe in the mixture which is its complete complement (Wallace, et al., Nucl. Acid Res., 9:879, 1981; Maniatis, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, N.Y. 1989).
- The development of specific DNA sequences encoding FHF-2 can also be obtained by: 1) isolation of double-stranded DNA sequences from the genomic DNA; 2) chemical manufacture of a DNA sequence to provide the necessary codons for the polypeptide of interest; and 3) in vitro synthesis of a double-stranded DNA sequence by reverse transcription of mRNA isolated from a eukaryotic donor cell. In the latter case, a double-stranded DNA complement of mRNA is eventually formed which is generally referred to as cDNA.
- Of the three above-noted methods for developing specific DNA sequences for use in recombinant procedures, the isolation of genomic DNA isolates is the least common. This is especially true when it is desirable to obtain the microbial expression of mammalian polypeptides due to the presence of introns.
- The synthesis of DNA sequences is frequently the method of choice when the entire sequence of amino acid residues of the desired polypeptide product is known. When the entire sequence of amino acid residues of the desired polypeptide is not known, the direct synthesis of DNA sequences is not possible and the method of choice is the synthesis of cDNA sequences. Among the standard procedures for isolating cDNA sequences of interest is the formation of plasmid- or phage-carrying cDNA libraries which are derived from reverse transcription of mRNA which is abundant in donor cells that have a high level of genetic expression. When used in combination with polymerase chain reaction technology, even rare expression products can be cloned. In those cases where significant portions of the amino acid sequence of the polypeptide are known, the production of labeled single or double-stranded DNA or RNA probe sequences duplicating a sequence putatively present in the target cDNA may be employed in DNA/DNA hybridization procedures which are carried out on cloned copies of the cDNA which have been denatured into a single-stranded form (Jay, et al., Nucl. Acid Res., 11:2325, 1983).
- A cDNA expression library, such as lambda gt11, can be screened indirectly for FHF-2 peptides having at least one epitope, using antibodies specific for FHF-2. Such antibodies can be either polyclonally or monoclonally derived and used to detect expression product indicative of the presence of FHF-2 cDNA.
- DNA sequences encoding FHF-2 can be expressed in vitro by DNA transfer into a suitable host cell. “Host cells” are cells in which a vector can be propagated and its DNA expressed. The term also includes any progeny of the subject host cell. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. However, such progeny are included when the term “host cell” is used. Methods of stable transfer, meaning that the foreign DNA is continuously maintained in the host, are known in the art.
- In the present invention, the FHF-2 polynucleotide sequences may be inserted into a recombinant expression vector. The term “recombinant expression vector” refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of the FHF-2 genetic sequences. Such expression vectors contain a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host. The expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use in the present invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg, et al., Gene, 56:125, 1987), the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, J. Biol. Chem., 263:3521, 1988) and baculovirus-derived vectors for expression in insect cells. The DNA segment can be present in the vector operably linked to regulatory elements, for example, a promoter (e.g., T7,
metallothionein 1, or polyhedrin promoters). - Polynucleotide sequences encoding FHF-2 can be expressed in either prokaryotes or eukaryotes. Hosts can include microbial, yeast, insect and mammalian organisms. Methods of expressing DNA sequences having eukaryotic or viral sequences in prokaryotes are well known in the art. Biologically functional viral and plasmid DNA vectors capable of expression and replication in a host are known in the art. Such vectors are used to incorporate DNA sequences of the invention.
- Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as E. coli, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl2 method using procedures well known in the art. Alternatively, MgCl2 or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell if desired.
- When the host is a eukaryote, such methods of transfection of DNA as calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors may be used. Eukaryotic cells can also be cotransformed with DNA sequences encoding the FHF-2 of the invention, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein. (see for example, Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982).
- Isolation and purification of microbial expressed polypeptide, or fragments thereof, provided by the invention, may be carried out by conventional means including preparative chromatography and immunological separations involving monoclonal or polyclonal antibodies.
- The FHF-2 polypeptides of the invention can also be used to produce antibodies which are immunoreactive or bind to epitopes of the FHF-2 polypeptides. Antibody which consists essentially of pooled monoclonal antibodies with different epitopic specificities, as well as distinct monoclonal antibody preparations are provided. Monoclonal antibodies are made from antigen containing fragments of the protein by methods well known in the art (Kohler, et al., Nature, 256:495, 1975; Current Protocols in Molecular Biology, Ausubel, et al., ed., 1989).
- The term “antibody” as used in this invention includes intact molecules as well as fragments thereof, such as Fab, F(ab′)2, and Fv which are capable of binding the epitopic determinant. These antibody fragments retain some ability to selectively bind with its antigen or receptor and are defined as follows:
- (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain;
- (2) Fab′, the fragment of an antibody molecule can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab′ fragments are obtained per antibody molecule;
- (3) (Fab′)2, the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab′)2 is a dimer of two Fab′ fragments held together by two disulfide bonds;
- (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and
- (5) Single chain antibody (“SCA”), defined as a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule.
- Methods of making these fragments are known in the art. (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1988), incorporated herein by reference).
- As used in this invention, the term “epitope” means any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics.
- Antibodies which bind to the FHF-2 polypeptide of the invention can be prepared using an intact polypeptide or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or a peptide used to immunize an animal can be derived from translated cDNA (see for example, EXAMPLE 4) or chemical synthesis which can be conjugated to a carrier protein, if desired. Such commonly used carriers which are chemically coupled to the peptide include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid. The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).
- If desired, polyclonal or monoclonal antibodies can be further purified, for example, by binding to and elution from a matrix to which the polypeptide or a peptide to which the antibodies were raised is bound. Those of skill in the art will know of various techniques common in the immunology arts for purification and/or concentration of polyclonal antibodies, as well as monoclonal antibodies (See for example, Coligan, et al.,
Unit 9, Current Protocols in Immunology, Wiley Interscience, 1994, incorporated by reference). - It is also possible to use the anti-idiotype technology to produce monoclonal antibodies which mimic an epitope. For example, an anti-idiotypic monoclonal antibody made to a first monoclonal antibody will have a binding domain in the hypervariable region which is the “image” of the epitope bound by the first monoclonal antibody.
- The term “cell-proliferative disorder” denotes malignant as well as non-malignant cell populations which often appear to differ from the surrounding tissue both morphologically and genotypically. Malignant cells (i.e. cancer) develop as a result of a multistep process. The FHF-2 polynucleotide that is an antisense molecule is useful in treating malignancies of the various organ systems, particularly, for example, cells in the central nervous system, including neural tissue, heart, and cells of the eye. Essentially, any disorder which is etiologically linked to altered expression of FHF-2 could be considered susceptible to treatment with a FHF-2 suppressing reagent. One such disorder is a malignant cell proliferative disorder, for example.
- For purposes of the invention, an antibody or nucleic acid probe specific for FHF-2 may be used to detect FHF-2 polypeptide (using antibody) or polynucleotide (using nucleic acid probe) in biological tissues or fluids. The invention provides a method for detecting a cell proliferative disorder of cardiac tissue or neural tissue, for example, which comprises contacting an anti-FHF-2 antibody or nucleic acid probe with a cell suspected of having a FHF-2 associated disorder and detecting binding of FHF-2 antigen or mRNA to the antibody or nucleic acid probe, respectively. The antibody or nucleic acid probe reactive with FHF-2 is preferably labeled with a compound which allows detection of binding to FHF-2. Any specimen containing a detectable amount of antigen can be used. A preferred sample of this invention is neural tissue or heart tissue. The level of FHF-2 in the suspect cell can be compared with the level in a normal cell to determine whether the subject has a FHF-2-associated cell proliferative disorder. Preferably the subject is human.
- When the cell component is nucleic acid, it may be necessary to amplify the nucleic acid prior to binding with an FHF-2 specific probe. Preferably, polymerase chain reaction (PCR) is used, however, other nucleic acid amplification procedures such as ligase chain reaction (LCR), ligated activated transcription (LAT) and nucleic acid sequence-based amplification (NASBA) may be used.
- The antibodies of the invention can be used in any subject in which it is desirable to administer in vitro or in vivo immunodiagnosis or immunotherapy. The antibodies of the invention are suited for use, for example, in immunoassays in which they can be utilized in liquid phase or bound to a solid phase carrier. In addition, the antibodies in these immunoassays can be detectably labeled in various ways. Examples of types of immunoassays which can utilize antibodies of the invention are competitive and non-competitive immunoassays in either a direct or indirect format. Examples of such immunoassays are the radioimmunoassay (RIA) and the sandwich (immunometric) assay. Detection of the antigens using the antibodies of the invention can be done utilizing immunoassays which are run in either the forward, reverse, or simultaneous modes, including immunohistochemical assays on physiological samples. Those of skill in the art will know, or can readily discern, other immunoassay formats without undue experimentation.
- The antibodies of the invention can be bound to many different carriers and used to detect the presence of an antigen comprising the polypeptide of the invention. Examples of well-known carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and magnetite. The nature of the carrier can be either soluble or insoluble for purposes of the invention. Those skilled in the art will know of other suitable carriers for binding antibodies, or will be able to ascertain such, using routine experimentation.
- There are many different labels and methods of labeling known to those of ordinary skill in the art. Examples of the types of labels which can be used in the present invention include enzymes, radioisotopes, fluorescent compounds, colloidal metals, chemiluminescent compounds, phosphorescent compounds, and bioluminescent compounds. Those of ordinary skill in the art will know of other suitable labels for binding to the antibody, or will be able to ascertain such, using routine experimentation.
- Another technique which may also result in greater sensitivity consists of coupling the antibodies to low molecular weight haptens. These haptens can then be specifically detected by means of a second reaction. For example, it is common to use such haptens as biotin, which reacts with avidin, or dinitrophenyl, puridoxal, and fluorescein, which can react with specific antihapten antibodies.
- In using the monoclonal antibodies of the invention for the in vivo detection of antigen, the detectably labeled antibody is given a dose which is diagnostically effective. The term “diagnostically effective” means that the amount of detectably labeled monoclonal antibody is administered in sufficient quantity to enable detection of the site having the antigen comprising a polypeptide of the invention for which the monoclonal antibodies are specific.
- The concentration of detectably labeled monoclonal antibody which is administered should be sufficient such that the binding to those cells having the polypeptide is detectable compared to the background. Further, it is desirable that the detectably labeled monoclonal antibody be rapidly cleared from the circulatory system in order to give the best target-to-background signal ratio.
- As a rule, the dosage of detectably labeled monoclonal antibody for in vivo diagnosis will vary depending on such factors as age, sex, and extent of disease of the individual. Such dosages may vary, for example, depending on whether multiple injections are given, antigenic burden, and other factors known to those of skill in the art.
- For in vivo diagnostic imaging, the type of detection instrument available is a major factor in selecting a given radioisotope. The radioisotope chosen must have a type of decay which is detectable for a given type of instrument. Still another important factor in selecting a radioisotope for in vivo diagnosis is that deleterious radiation with respect to the host is minimized. Ideally, a radioisotope used for in vivo imaging will lack a particle emission, but produce a large number of photons in the 140-250 keV range, which may readily be detected by conventional gamma cameras.
- For in vivo diagnosis radioisotopes may be bound to immunoglobulin either directly or indirectly by using an intermediate functional group. Intermediate functional groups which often are used to bind radioisotopes which exist as metallic ions to immunoglobulins are the bifunctional chelating agents such as diethylenetriaminepentacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA) and similar molecules. Typical examples of metallic ions which can be bound to the monoclonal antibodies of the invention are 111In, 97Ru 67Ga 68Ga 72As 89Zr, and 201Tl.
- The monoclonal antibodies of the invention can also be labeled with a paramagnetic isotope for purposes of in vivo diagnosis, as in magnetic resonance imaging (MRI) or electron spin resonance (ESR). In general, any conventional method for visualizing diagnostic imaging can be utilized. Usually gamma and positron emitting radioisotopes are used for camera imaging and paramagnetic isotopes for MRI. Elements which are particularly useful in such techniques include 157Gd, 55Mn, 162Dy, 52Cr, and 56Fe.
- The monoclonal antibodies or polynucleotides of the invention can be used in vitro and in vivo to monitor the course of amelioration of a FHF-2-associated disease in a subject. Thus, for example, by measuring the increase or decrease in the number of cells expressing antigen comprising a polypeptide of the invention or changes in the concentration of such antigen present in various body fluids, it would be possible to determine whether a particular therapeutic regimen aimed at ameliorating the FHF-2-associated disease is effective. The term “ameliorate” denotes a lessening of the detrimental effect of the FHF-2-associated disease in the subject receiving therapy.
- The present invention identifies a nucleotide sequence that can be expressed in an altered manner as compared to expression in a normal cell, therefore it is possible to design appropriate therapeutic or diagnostic techniques directed to this sequence. Detection of elevated levels of FHF-2 expression is accomplished by hybridization of nucleic acids isolated from a cell suspected of having an FHF-2 associated proliferative disorder with an FHF-2 polynucleotide of the invention. Analyses, such as Northern Blot analysis, are utilized to quantitate expression of FHF-2. Other standard nucleic acid detection techniques will be known to those of skill in the art.
- Treatment of an FHF-2 associated cell proliferative disorder include modulation of FHF-2 gene expression and FHF-2 activity. The term “modulate” envisions the suppression of expression of FHF-2 when it is over-expressed, or augmentation of FHF-2 expression when it is under-expressed. Where a cell-proliferative disorder is associated with the expression of FHF-2, nucleic acid sequences that interfere with FHF-2 expression at the translational level can be used. This approach utilizes, for example, antisense nucleic acid, ribozymes, or triplex agents to block transcription or translation of a specific FHF-2 mRNA, either by masking that mRNA with an antisense nucleic acid or triplex agent, or by cleaving it with a ribozyme. Such disorders include neurodegenerative diseases, for example.
- Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule (Weintraub, Scientific American, 262:40, 1990). In the cell, the antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule. The antisense nucleic acids interfere with the translation of the mRNA, since the cell will not translate a mRNA that is double-stranded. Antisense oligomers of about 15 nucleotides are preferred, since they are easily synthesized and are less likely to cause problems than larger molecules when introduced into the target FHF-2-producing cell. The use of antisense methods to inhibit the in vitro translation of genes is well known in the art (Marcus-Sakura, AnalBiochem., 172:289, 1988).
- Use of an oligonucleotide to stall transcription is known as the triplex strategy since the oligomer winds around double-helical DNA, forming a three-strand helix. Therefore, these triplex compounds can be designed to recognize a unique site on a chosen gene (Maher, et al., Antisense Res. and Dev., 1(3):227, 1991; Helene, C., Anticancer Drug Design, 6(6):569, 1991).
- Ribozymes are RNA molecules possessing the ability to specifically cleave other single-stranded RNA in a manner analogous to DNA restriction endonucleases. Through the modification of nucleotide sequences which encode these RNAs, it is possible to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, J. Amer. Med. Assn., 260:3030, 1988). A major advantage of this approach is that, because they are sequence-specific, only mRNAs with particular sequences are inactivated.
- There are two basic types of ribozymes namely, tetrahymena-type (Hasselhoff, Nature, 334:585, 1988) and “hammerhead”-type. Tetrahymena-type ribozymes recognize sequences which are four bases in length, while “hammerhead”-type ribozymes recognize base sequences 11-18 bases in length. The longer the recognition sequence, the greater the likelihood that the sequence will occur exclusively in the target mRNA species. Consequently, hammerhead-type ribozymes are preferable to tetrahymena-type ribozymes for inactivating a specific mRNA species and 18-based recognition sequences are preferable to shorter recognition sequences.
- The present invention also provides gene therapy for the treatment of cell proliferative or immunologic disorders which are mediated by FHF-2 protein. Such therapy would achieve its therapeutic effect by introduction of the FHF-2 antisense polynucleotide into cells having the proliferative disorder. Delivery of antisense FHF-2 polynucleotide can be achieved using a recombinant expression vector such as a chimeric virus or a colloidal dispersion system. Especially preferred for therapeutic delivery of antisense sequences is the use of targeted liposomes.
- Various viral vectors which can be utilized for gene therapy as taught herein include adenovirus, herpes virus, vaccinia, or, preferably, an RNA virus such as a retrovirus. Preferably, the retroviral vector is a derivative of a murine or avian retrovirus. Examples of retroviral vectors in which a single foreign gene can be inserted include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), and Rous Sarcoma Virus (RSV). Preferably, when the subject is a human, a vector such as the gibbon ape leukemia virus (GaLV) is utilized. A number of additional retroviral vectors can incorporate multiple genes. All of these vectors can transfer or incorporate a gene for a selectable marker so that transduced cells can be identified and generated. By inserting a FHF-2 sequence of interest into the viral vector, along with another gene which encodes the ligand for a receptor on a specific target cell, for example, the vector is now target specific. Retroviral vectors can be made target specific by attaching, for example, a sugar, a glycolipid, or a protein. Preferred targeting is accomplished by using an antibody to target the retroviral vector. Those of skill in the art will know of, or can readily ascertain without undue experimentation, specific polynucleotide sequences which can be inserted into the retroviral genome or attached to a viral envelope to allow target specific delivery of the retroviral vector containing the FHF-2 antisense polynucleotide.
- Since recombinant retroviruses are defective, they require assistance in order to produce infectious vector particles. This assistance can be provided, for example, by using helper cell lines that contain plasmids encoding all of the structural genes of the retrovirus under the control of regulatory sequences within the LTR. These plasmids are missing a nucleotide sequence which enables the packaging mechanism to recognize an RNA transcript for e-ncapsidation. Helper cell lines which have deletions of the packaging signal include, but are not limited to Ψ2, PA317 and
PA 12, for example. These cell lines produce empty virions, since no genome is packaged. If a retroviral vector is introduced into such cells in which the packaging signal is intact, but the structural genes are replaced by other genes of interest, the vector can be packaged and vector virion produced. - Alternatively, NIH 3T3 or other tissue culture cells can be directly transfected with plasmids encoding the retroviral structural genes gag, pol and env, by conventional calcium phosphate transfection. These cells are then transfected with the vector plasmid containing the genes of interest. The resulting cells release the retroviral vector into the culture medium.
- Another targeted delivery system for FHF-2 antisense polynucleotides is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome. Liposomes are artificial membrane vesicles which are useful as delivery vehicles in vitro and in vivo. It has been shown that large unilamellar vesicles (LUV). which range in size from 0.2-4.0 μm can encapsulate a substantial percentage of an aqueous buffer containing large macro-molecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., Trends Biochem. Sci., 6:77, 1981). In addition to mammalian cells, liposomes have been used for delivery of polynucleotides in plant, yeast and bacterial cells. In order for a liposome to be an efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the genes of interest at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information (Mannino, et al., Biotechniques, 6:682, 1988).
- The composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.
- Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Particularly useful are d-iacylphosphatidylglycerols, where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.
- The targeting of liposomes can be classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and organelle-specific. Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system (RES) in organs which contain sinusoidal capillaries. Active targeting, on the other hand, involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.
- The surface of the targeted delivery system may be modified in a variety of ways. In the case of a liposomal targeted delivery system, lipid groups can be incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer. Various linking groups can be used for joining the lipid chains to the targeting ligand.
- Due to the expression of FHF-2 in heart, eye, and brain, or neural tissue, there are a variety of applications using the polypeptide, polynucleotide, and antibodies of the invention, related to these tissues. Such applications include treatment of cell proliferative and immunologic disorders involving these and other tissues. In addition, FHF-2 may be useful in various gene therapy procedures.
- The identification of a novel member of the FGF family provides a useful tool for diagnosis, prognosis and therapeutic strategies associated with FHF-2 mediated disorders. Measurement of FHF-2 levels using anti-FHF-2 antibodies is useful diagnostic for following the progression or recovery from diseases of the nervous system, including: cancer, stroke, neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease, retinal diseases such as retinitis p-igmentosa, or viral encephalitis. The presence of high levels of FHF-2 in the central nervous system suggests that the observed low level of FHF-2 in a number of peripheral tissues could reflect FHF-2 in peripheral nerve, and therefore measurement of FHF-2 levels using anti-FHF-2 antibodies could be diagnostic for peripheral neuropathy. The presence of high levels of FHF-2 in the heart suggests that measurement of FHF-2 levels using anti-FHF-2 antibodies is useful as a diagnostic for myocardial infarction, viral endocarditis, or other cardiac disorders.
- Like other members of the FGF family, FHF-2 likely has mitogenic and/or cell survival activity, therefore FHF-2 or an analogue that mimics FHF-2 action could be used to promote tissue repair or replacement. The presence of FHF-2 in the CNS suggests such a therapeutic role in diseases of the nervous system, including: stroke, neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease, or in retinal degenerative diseases such as retinitis pigmentosa or macular degeneration, or in peripheral neuropathies. The presence of high levels of FHF-2 in the heart suggests that FHF-2 or an analogue of FHF-2 could be used to accelerate recovery from myocardial infarction or could promote increased cardiac output by increasing heart muscle.
- Conversely, blocking FHF-2 action either with anti-FHF-2 antibodies or with an FHF-2 antagonist might slow or ameliorate diseases in which excess cell growth is pathological, most obviously cancer.
- The following examples are intended to illustrate but not limit the invention. While they are typical of those that might be used, other procedures known to those skilled in the art may alternatively be used.
- To identify novel gene products expressed in the human retina, random segments of human retina cDNA clones were partially sequenced, and the resulting partial sequences compared to the sequences available in the public databases.
- In detail, an adult human retina cDNA library constructed in lambda gt10 (Nathans, et al., Science, 232: 193, 1986) was amplified, and the cDNA inserts were excised en mass by cleavage with EcoR I and purified free of the vector by agarose gel electrophoresis. Following heat denaturation of the purified cDNA inserts, a synthetic oligonucleotide containing an EcoR I site at its 5′ end and six random nucleotides at its 3′ end (5′ GACGAGATATTAGAATTCTACTCGNNNNNN) (SEQ ID NO:3) was used to prime two sequential rounds of DNA synthesis in the presence of the Klenow fragment of E. coli DNA polymerase. The resulting duplex molecules were amplified using the polymerase chain reaction (PCR) with a primer corresponding to the unique 5′ flanking sequence (5′ CCCCCCCCCGACGAGATATTAGAATTCTACTCG) (SEQ ID NO:4). These PCR products, representing a random sampling of the original cDNA inserts, were cleaved with EcoR I, size fractionated by preparative agarose gel electrophoresis to include only segments of approximately 500 bp in length, and cloned into lambda gt10. Three thousand single plaques from this derivative library were arrayed in 96-well trays and from these clones the inserts were amplified by PCR using flanking vector primers and then sequenced using the dideoxy method and automated fluorescent detection (Applied Biosystems). A single sequencing run from one end of each insert was conceptually translated on both strands in all three reading frames and the six resulting amino acid sequences were used to search for homology in the GenBank nonredundant protein database using the BLASTX searching algorithm.
- One partial cDNA sequence was found that showed statistically significant homology to previously described members of the FGF family. Using this partial cDNA as a probe, multiple independent cDNA clones were isolated from the human retina cDNA library, including two that encompass the entire open reading frame and from which complete nucleotide sequences were determined. This sequence was named FHF-1 and is the subject of a pending patent application (U.S. patent application Ser. No. 08/439,725, “Fibroblast Growth Factor Homologous Factor-1 (FHF-1) and Methods of Use”, Nathans et al., filed May 12, 1995). A search of partial cDNA sequences (‘expressed sequence tags’, ESTs) in the public databases revealed a human adult testis cDNA fragment (NCBI ID 28057, EST ID EST06895, Genbank ID T09003; Adams, et al., Nature Genetics, 4: 373, 1993) with strong homology to FHF-1, but only weak homology to other members of the FGF family. The homology between this EST and other members of the FGF family is sufficiently low that no indication of that homology was noted in the description associated with the clone in Genbank or in the publication describing the EST sequence (Adams, et al., supra, 1993). Based on the EST sequence, this fragment was amplified by PCR from a human retina cDNA library and used as a probe to isolate multiple independent cDNA clones from that library, including two that encompass the entire open reading frame and from which complete nucleotide sequences were determined. This sequence was named FHF-2.
-
FIG. 1 shows the sequence of human FHF-2 deduced from the nucleotide sequences of two independent human retina cDNA clones. The primary translation product of human FHF-2 is predicted to be 245 amino acids in length. The human FHF-2 inititiator methionine codon shown inFIG. 1 at position 352-354 corresponds to the location of the initiator methionine codon of FHF-1 when the two sequences are aligned; a good consensus ribosome binding site (TGGCCATGG; Kozak, Nucleic Acids Res., 15: 8125, 1987) (SEQ ID NO:5) is found at this position. The next methionine codon within the open reading frame is encountered 124codons 3′ of the putative initiator methionine codon. As observed for aFGF and bFGF, the amino-terminus of the primary translation product of FHF-2 does not conform to the consensus sequence for a signal peptide to direct cotranslational insertion across the endoplasmic reticulum membrane. The FHF-2 sequence has one potential asn-X-ser/thr site for asparagine-linked glycosylation four amino acids from the carboxy-terminus. - Alignment of FHF-2 with the other known members of the FGF family is shown in
FIG. 2 and a dendrogram showing the degree of amino acid similarity is shown inFIG. 3 . The most homologous FGF family member is FGF-9 which shows 28% amino acid identity with FHF-2 when aligned with 6 gaps. Note that in the central region of each polypeptide, all FGF family members, including FHF-2, share 11 invariant amino acids. - The chromosomal location of FHF-2 was determined by probing a Southern blot containing restriction enzyme digested DNA derived from a panel of 24 human-mouse and human-hamster cell lines, each containing a different human chromosome (Oncor, Gaithersburg, Md.). As seen in
FIG. 4 , hybridization of the human FHF-2 probe to human, mouse, and hamster genomic DNA produces distinct hybridizing fragment sizes. The human-specific hybridization pattern is seen only in the lane corresponding to the hybrid cell line carrying the human X-chromosome. - To express FHF-2 in human cells, the complete open reading frame was inserted into the eukaryotic expression vector pCIS (Gorman, et al., DNA Protein Eng. Tech., 2: 3, 1990). To increase the efficiency of translation, the region immediately 5′ of the initiator methionine coding was converted to an optimal ribosome binding site (CCACCATGG) (SEQ ID NO:5) by cutting the FHF-2 coding region at the initiator methionine with Nco 1 (which recognizes CCATGG) and ligating to the expression vector. Following transient transfection of human embryonic kidney cells with the expression construct and a plasmid expressing the simian virus 40 (SV40) large T-antigen (pRSV-TAg; Gorman et al., supra), cells were metabolically labeled with 35S methionine for 6 hours in the absence of serum. As shown in
FIG. 5 , cells transfected with FHF-2 synthesize a single polypeptide with an apparent molecular mass of 30 kD that is not produced by untransfected cells or by cells transfected with an unrelated construct. This polypeptide corresponds closely to the predicted molecular mass of the primary translation product, 27.6 kD.FIG. 5 also shows that cells transfected with a human growth hormone (hGH) expression plasmid efficiently secrete hGH, whereas FHF-2 accumulates within the transfected cells and fails to be secreted in detectable quantities. - To determine the tissue distribution of FHF-2 mRNA, RNase protection analysis was performed on total RNA from mouse brain, eye, heart, kidney, liver, lung, spleen, and testis, as well as a yeast tRNA negative control. The probe used was derived from a segment of the mouse FHF-2 gene isolated by hybridization with the full-length human FHF-2 cDNA. As seen in
FIG. 6 , the highest levels of FHF-2 expression are in the brain, eye, and heart. Very low levels of FHF-2 expression were detected in all of the other tisssues on a longer exposure of the autoradiogram. - Although the invention has been described with reference to the presently preferred embodiment, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.
Claims (3)
1. An isolated antibody that binds to an FHF-2 polypeptide comprising the amino acid sequence set forth in SEQ ID NO.:2 or immunoreactive fragments of the FHF-2 polypeptide.
2. The isolated antibody of claim 1 , wherein the antibody is polyclonal.
3. The isolated antibody of claim 2 , wherein the antibody is monoclonal.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/514,821 US20070066812A1 (en) | 1995-05-12 | 2006-09-01 | Fibroblast growth factor homologous factor-2 and methods of use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/438,439 US5876967A (en) | 1995-05-12 | 1995-05-12 | Fibroblast growth factor homologous factor-2 and methods of use |
US26100799A | 1999-03-02 | 1999-03-02 | |
US10/192,988 US20030166875A1 (en) | 1995-05-12 | 2002-07-10 | Fibroblast growth factor homologous factor-2 and methods of use |
US11/514,821 US20070066812A1 (en) | 1995-05-12 | 2006-09-01 | Fibroblast growth factor homologous factor-2 and methods of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/192,988 Continuation US20030166875A1 (en) | 1995-05-12 | 2002-07-10 | Fibroblast growth factor homologous factor-2 and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070066812A1 true US20070066812A1 (en) | 2007-03-22 |
Family
ID=23740672
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/438,439 Expired - Fee Related US5876967A (en) | 1995-05-12 | 1995-05-12 | Fibroblast growth factor homologous factor-2 and methods of use |
US10/192,988 Abandoned US20030166875A1 (en) | 1995-05-12 | 2002-07-10 | Fibroblast growth factor homologous factor-2 and methods of use |
US11/514,821 Abandoned US20070066812A1 (en) | 1995-05-12 | 2006-09-01 | Fibroblast growth factor homologous factor-2 and methods of use |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/438,439 Expired - Fee Related US5876967A (en) | 1995-05-12 | 1995-05-12 | Fibroblast growth factor homologous factor-2 and methods of use |
US10/192,988 Abandoned US20030166875A1 (en) | 1995-05-12 | 2002-07-10 | Fibroblast growth factor homologous factor-2 and methods of use |
Country Status (9)
Country | Link |
---|---|
US (3) | US5876967A (en) |
EP (1) | EP0832109B1 (en) |
JP (1) | JP2001505526A (en) |
AT (1) | ATE403673T1 (en) |
AU (1) | AU708772B2 (en) |
CA (1) | CA2220917A1 (en) |
DE (1) | DE69637624D1 (en) |
ES (1) | ES2311290T3 (en) |
WO (1) | WO1996035716A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110893A (en) * | 1995-06-05 | 2000-08-29 | Human Genome Sciences, Inc. | Fibroblast growth factor 11 |
US6605441B1 (en) * | 1995-06-05 | 2003-08-12 | Human Genome Sciences, Inc. | Antibodies against fibroblast growth factor 11 |
AU712297B2 (en) * | 1995-06-05 | 1999-11-04 | Human Genome Sciences, Inc. | Fibroblast growth factor 11 |
US6020189A (en) | 1996-08-30 | 2000-02-01 | The Johns Hopkins University School Of Medicine | Fibroblast growth factor homologous factors (FHFs) and methods of use |
WO2010129784A2 (en) * | 2009-05-06 | 2010-11-11 | The Research Foundation Of The City University Of New York | Isolated a-type fhf n-terminal domain peptides and methods of use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2217301A1 (en) * | 1995-06-05 | 1996-12-12 | Human Genome Sciences, Inc. | Fibroblast growth factor 15 |
AU712297B2 (en) * | 1995-06-05 | 1999-11-04 | Human Genome Sciences, Inc. | Fibroblast growth factor 11 |
EP0935654A4 (en) * | 1996-03-21 | 2000-07-05 | Univ Johns Hopkins Med | Fibroblast growth factor homologous factor-3 (fhf-3) and methods of use |
-
1995
- 1995-05-12 US US08/438,439 patent/US5876967A/en not_active Expired - Fee Related
-
1996
- 1996-05-10 CA CA002220917A patent/CA2220917A1/en not_active Abandoned
- 1996-05-10 AT AT96915686T patent/ATE403673T1/en not_active IP Right Cessation
- 1996-05-10 WO PCT/US1996/006665 patent/WO1996035716A1/en active Application Filing
- 1996-05-10 EP EP96915686A patent/EP0832109B1/en not_active Expired - Lifetime
- 1996-05-10 JP JP53427496A patent/JP2001505526A/en not_active Ceased
- 1996-05-10 ES ES96915686T patent/ES2311290T3/en not_active Expired - Lifetime
- 1996-05-10 DE DE69637624T patent/DE69637624D1/en not_active Expired - Fee Related
- 1996-05-10 AU AU57398/96A patent/AU708772B2/en not_active Ceased
-
2002
- 2002-07-10 US US10/192,988 patent/US20030166875A1/en not_active Abandoned
-
2006
- 2006-09-01 US US11/514,821 patent/US20070066812A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0832109A1 (en) | 1998-04-01 |
US5876967A (en) | 1999-03-02 |
WO1996035716A1 (en) | 1996-11-14 |
AU5739896A (en) | 1996-11-29 |
EP0832109B1 (en) | 2008-08-06 |
JP2001505526A (en) | 2001-04-24 |
DE69637624D1 (en) | 2008-09-18 |
ES2311290T3 (en) | 2009-02-01 |
CA2220917A1 (en) | 1996-11-14 |
AU708772B2 (en) | 1999-08-12 |
ATE403673T1 (en) | 2008-08-15 |
US20030166875A1 (en) | 2003-09-04 |
EP0832109A4 (en) | 2000-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5872226A (en) | Fibroblast growth factor homologous factor-1 (FHF-1) | |
US7074574B2 (en) | Method of detecting growth differentiation factor-7 (GDF-7) using GDF-7 antibodies | |
WO1996035708A9 (en) | Fibroblast growth factor homologous factor-1 (fhf-1) and methods of use | |
US20030023073A1 (en) | Growth differentiation factor-15 | |
US20060153849A1 (en) | Methods of treatment with an antibody that suppresses growth differentiation factor-14 activity | |
JPH10502811A (en) | Growth differentiation factor-11 | |
US20070066812A1 (en) | Fibroblast growth factor homologous factor-2 and methods of use | |
US7270963B2 (en) | Growth differentiation factor, lefty-2 | |
AU719538B2 (en) | Fibroblast growth factor homologous factor-3 (FHF-3) and methods of use | |
WO1999006444A1 (en) | GROWTH DIFFERENTIATION FACTOR, Lefty-1 | |
WO1996035716A9 (en) | Fibroblast growth factor homologous factor-2 and methods of use | |
US7495075B2 (en) | Growth differentiation factor-16 | |
US5831054A (en) | Polynucleotide encoding growth differentiation factor-12 | |
WO1999006556A1 (en) | Growth differentiation factor-16 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |